DK4175619T3 - Aerosol drug delivery compositions, methods, and systems - Google Patents

Aerosol drug delivery compositions, methods, and systems Download PDF

Info

Publication number
DK4175619T3
DK4175619T3 DK22748656.0T DK22748656T DK4175619T3 DK 4175619 T3 DK4175619 T3 DK 4175619T3 DK 22748656 T DK22748656 T DK 22748656T DK 4175619 T3 DK4175619 T3 DK 4175619T3
Authority
DK
Denmark
Prior art keywords
systems
methods
drug delivery
delivery compositions
aerosol drug
Prior art date
Application number
DK22748656.0T
Other languages
Danish (da)
Inventor
Vidya Joshi
James Archbell
Kellisa Lachacz
Charina Lampa
Lauren Mello
Gertrude Gutierrez
David Lechuga-Ballesteros
Penny Tan
Michael RIEBE
Original Assignee
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Pharmaceuticals Lp filed Critical Astrazeneca Pharmaceuticals Lp
Application granted granted Critical
Publication of DK4175619T3 publication Critical patent/DK4175619T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK22748656.0T 2021-07-09 2022-07-08 Aerosol drug delivery compositions, methods, and systems DK4175619T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220362P 2021-07-09 2021-07-09
US202163282356P 2021-11-23 2021-11-23
PCT/US2022/036543 WO2023283439A1 (en) 2021-07-09 2022-07-08 Compositions, methods and systems for aerosol drug delivery

Publications (1)

Publication Number Publication Date
DK4175619T3 true DK4175619T3 (en) 2024-05-06

Family

ID=82748203

Family Applications (3)

Application Number Title Priority Date Filing Date
DK23155432.0T DK4197528T3 (en) 2021-07-09 2022-07-08 Aerosol drug delivery compositions, methods, and systems
DK22751897.4T DK4175620T3 (en) 2021-07-09 2022-07-08 Aerosol drug delivery compositions, methods, and systems
DK22748656.0T DK4175619T3 (en) 2021-07-09 2022-07-08 Aerosol drug delivery compositions, methods, and systems

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK23155432.0T DK4197528T3 (en) 2021-07-09 2022-07-08 Aerosol drug delivery compositions, methods, and systems
DK22751897.4T DK4175620T3 (en) 2021-07-09 2022-07-08 Aerosol drug delivery compositions, methods, and systems

Country Status (14)

Country Link
US (1) US20230026203A1 (en)
EP (4) EP4175619B1 (en)
KR (3) KR20240042438A (en)
AU (3) AU2022306682A1 (en)
CA (3) CA3226557A1 (en)
CO (3) CO2024000631A2 (en)
DK (3) DK4197528T3 (en)
DO (3) DOP2024000004A (en)
FI (2) FI4175619T3 (en)
IL (3) IL309908A (en)
LT (2) LT4197528T (en)
PE (2) PE20240808A1 (en)
TW (3) TW202317081A (en)
WO (3) WO2023283441A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023212191A1 (en) * 2022-04-28 2023-11-02 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37872A (en) 1863-03-10 Improved mast-hoop
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (en) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
ZA81976B (en) 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
ATE8790T1 (en) 1981-02-02 1984-08-15 Schering Corporation AROMATIC HETEROCYCLIC STEROID ESTER, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
DE3931041C2 (en) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
SE9302777D0 (en) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (en) 1993-12-28 1995-06-29 Ciba Geigy Ag Process for preparing an optically pure enantiomer of formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (en) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
CA2218074C (en) 1995-04-14 2002-10-08 Mohammed Eljamal Powdered pharmaceutical formulations having improved dispersibility
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
PT102343B (en) 1999-08-02 2003-11-28 Hovione Farmaciencia Sa METHOD FOR THE PREPARATION OF FUROATE MOMETHASONE
NZ518401A (en) 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
PT1606261E (en) 2003-03-10 2010-01-11 Nycomed Gmbh Novel process for the preparation of roflumilast
WO2005000267A2 (en) 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Method of particle formation
CN100560598C (en) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 The synthetic method of FLUTICASONE PROPIONATE
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3106149T3 (en) 2009-05-29 2020-06-01 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems
SG194896A1 (en) * 2011-05-17 2013-12-30 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents
WO2013072938A2 (en) 2011-11-09 2013-05-23 Mylan Laboratories Ltd An improved process for the preparation of roflumilast
CA2865972C (en) * 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
US9321726B2 (en) 2012-10-17 2016-04-26 Interquim, S.A. Process for preparing roflumilast
SG11201505835QA (en) * 2013-01-28 2015-08-28 Incozen Therapeutics Pvt Ltd Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
EP2999460A1 (en) * 2013-05-22 2016-03-30 Pearl Therapeutics, Inc. Compositions, methods&systems for respiratory delivery of three or more active agents
EP3694590B1 (en) 2017-10-09 2022-05-04 Pearl Therapeutics, Inc. Drug delivery systems

Also Published As

Publication number Publication date
FI4175619T3 (en) 2024-05-28
EP4197528A1 (en) 2023-06-21
DK4197528T3 (en) 2024-05-06
DOP2024000005A (en) 2024-04-15
PE20240808A1 (en) 2024-04-18
WO2023283439A1 (en) 2023-01-12
WO2023283438A1 (en) 2023-01-12
EP4366695A1 (en) 2024-05-15
IL309888A (en) 2024-03-01
EP4197528B1 (en) 2024-04-03
TW202317079A (en) 2023-05-01
US20230026203A1 (en) 2023-01-26
FI4197528T3 (en) 2024-05-24
EP4175620A1 (en) 2023-05-10
EP4175620B1 (en) 2024-04-10
DK4175620T3 (en) 2024-06-03
LT4197528T (en) 2024-06-10
CO2024000631A2 (en) 2024-02-15
DOP2024000004A (en) 2024-04-15
IL309908A (en) 2024-03-01
AU2022308837A1 (en) 2024-01-25
TW202317080A (en) 2023-05-01
DOP2024000006A (en) 2024-04-15
TW202317081A (en) 2023-05-01
IL309907A (en) 2024-03-01
WO2023283441A1 (en) 2023-01-12
AU2022305962A1 (en) 2024-01-25
CA3226155A1 (en) 2023-01-12
EP4175619B1 (en) 2024-04-10
KR20240042438A (en) 2024-04-02
KR20240042436A (en) 2024-04-02
CA3226557A1 (en) 2023-01-12
LT4175619T (en) 2024-06-10
EP4175619A1 (en) 2023-05-10
CA3226153A1 (en) 2023-01-12
AU2022306682A1 (en) 2024-01-25
CO2024000748A2 (en) 2024-02-26
KR20240042437A (en) 2024-04-02
PE20240807A1 (en) 2024-04-18
CO2024000742A2 (en) 2024-02-26

Similar Documents

Publication Publication Date Title
DK3506884T3 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICINES AND USES OF THESE
DK3681804T3 (en) Systems and procedures for delivery, storage and processing of materials in space
DK3453707T3 (en) BENZAZE PINDER, METHOD OF MANUFACTURE, PHARMACEUTICAL COMPOSITION AND USE
HK1246309A1 (en) De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
DK3524603T3 (en) FGFR4 INHIBITORS, MANUFACTURING METHOD AND PHARMACEUTICAL APPLICATION
DK3486242T3 (en) OXOPICOLINIDE DERIVATIVE, METHOD OF MANUFACTURE THEREOF AND PHARMACEUTICAL APPLICATION
DK3313817T3 (en) BICYCLIC DERIVATIVES, MANUFACTURING PROCEDURES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE
DK3426250T3 (en) TREATMENT OF A PATIENT WITH A CYP3A4 SUBSTRATED MEDICINAL PRODUCT CONTRAINDICATED FOR ADMINISTRATION WITH A STRONG CYP3A4 INHIBITOR
DK3326615T3 (en) CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA-DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS, AND COMPOSITIONS FOR SAME
DK3937902T3 (en) PHARMACEUTICAL DOSAGE FORM FOR APPLICATION TO MUCOUS MEMBRANES AND PROCEDURE FOR MANUFACTURE THE SAME
DK3278803T3 (en) Solid pharmaceutical dosage form of PARP inhibitor, and use of solid pharmaceutical dosage form of PARP inhibitor
DK3744316T3 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITION, METHOD OF PREPARATION THEREOF AND USE THEREOF
DK3404024T3 (en) QUINAZOLINE DERIVATIVE, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND USES
DK4175619T3 (en) Aerosol drug delivery compositions, methods, and systems
DK3452001T3 (en) DEVICE AND PROCEDURE FOR PACKAGING SOLID MEDICINES, DEVICE FOR STORAGE AND DELIVERY OF SUCH MEDICINAL PRODUCTS AND METHOD OF DELIVERY
DK3833682T3 (en) SUICIDE MOLECULAR COMPOSITIONS AND METHODS
DK3275454T3 (en) PHARMACEUTICAL COMPOSITION WITH SILYBINE, VE AND L-CARNITINE
ZA202108771B (en) Flavonoid polyphenol drug self-emulsifying composition, preparation method therefor, pharmaceutical composition thereof and application thereof
DK3707128T3 (en) INJECTABLE PHARMACEUTICAL ISOXAZOLINE COMPOSITIONS AND THEIR USE AGAINST PARASITIC INVASION
DK3688147T3 (en) PREVIOUSLY UNKNOWN DRUG DELIVERY SYSTEM AND METHODS OF DELIVERY THEREOF
DK3383397T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRIN, TENOFOVIRDISOPROXILFUMARAT AND LAMIVUDIN
SG11202102742RA (en) Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
IL287920A (en) An antigen-binding molecule, a pharmaceutical composition, and a method
DK3285835T3 (en) DOSAGE APPLIANCE AND MEDICINE FOR ADMINISTRATION
DK3373996T3 (en) Method for producing, using and administering activated stem cells